A randomized double-blinded study of CRSwNP patients with comorbid asthma also found that omalizumab, a recombinant humanized monoclonal antibody targeting IgE, reduced nasal polyp size and improved sinus CT scores in patients with CRSwNP. Here, IGHE is linked to nasal cavity polyp.